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Aims. We aim to evaluate the association of maternal gestational oral glucose tolerance test (OGTT) glucose concentrations with
anthropometry in the offspring from birth to 12 months in Tianjin, China.Methods. A total of 27,157 pregnant women underwent
OGTT during 26–30 weeks gestation, and their children had body weight/length measured from birth to 12 months old. Results.
Maternal OGTT glucose concentrations at 26–30 gestational weeks were positively associated with Z-scores for birth length-for-
gestational age and birth weight-for-length. Compared with infants born to mothers with normal glucose tolerance, infants born to
mothers with gestational diabetes mellitus (impaired glucose tolerance/new diabetes) had higher mean values of Z-scores for birth
length-for-gestational age (0.07/0.23; normal group −0.08) and birth weight-for-length (0.27/0.57; normal group −0.001), smaller
changes in mean values of Z-scores for length-for-age (0.75/0.62; normal group 0.94) and weight-for-length (0.18/−0.17; normal
group 0.37) from birth to month 3, and bigger changes in mean values in Z-scores for weight-for-length (0.07/0.12; normal group
0.02) from month 9 to 12. Conclusions. Abnormal maternal glucose tolerance during pregnancy was associated with higher birth
weight and birth length, less weight and length gain in the first 3 months of life, and more weight gain in the months 9–12 of life.
1. Introduction
Gestational diabetes mellitus (GDM) is increasingly com-
mon worldwide [1]. In China, the prevalence of GDM has
increased from 2.4% in 1999 to 6.8% in 2008 [2], now close
to the US level. One of the major concerns about GDM is
that it may be contributing to a vicious intergenerational
cycle of obesity and diabetes [3]. Women with a history of
GDM are at increased risk of type 2 diabetes and impaired
glucose tolerance (IGT) later in life [4], especially at the first
5 years after delivery [5]. The exposure to diabetes during
pregnancy is associated with increased risks of neonatal
adiposity, childhood obesity, insulin resistance, IGT, and type
2 diabetes in the offspring in some but not all studies [6–8].
Childhood obesity is a global problem. The prevalence
of childhood obesity is 6.7% in 2010 worldwide, and 70%
of obese adolescents become obese adults [9]. Hillier et al.
[10] found that a higher hyperglycemia level in pregnancy
was associated with an increased future risk of obesity in
their children at 5–7 years. The Hyperglycemia and Adverse
PregnancyOutcome (HAPO) study found a weak association
between maternal glucose during pregnancy and obesity in
the offspring at age 2 [11]. However, most previous studies
have paidmore attention to the association betweenmaternal
hyperglycemia and children obesity in the offspring of more
than 5 years old [8]. Few studies have examined whether
abnormal maternal glucose tolerance during pregnancy also
predicts weight gain in early infancy [12]. It has been
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suggested that rapidweight gain in infancy (<2 years old) pre-
dicts a later risk of obesity in childhood and adulthood [13].
The aim of the present study was to evaluate the association
of maternal OGTT glucose levels at 26–30 gestational weeks
with anthropometry in the offspring from birth to 12 months
in Tianjin, China.
2. Methods
2.1. Study Sample. Tianjin is the fourth largest city with over
12.9 million residents in Northern China, and 4.3 million
residents live in central urban districts.The prenatal care and
children health care in central urban districts are a routine
of a three-tier care system consisting of approximately 65
primary hospitals, 6 district-level Women’s and Children’s
Health Centers, and a city-level (Tianjin) Women’s and
Children’s Health Center (also including tertiary hospitals).
In Tianjin, all pregnant women are registered at the primary
hospitals, and in the 32nd gestational week, they are referred
to a secondary hospital or a tertiary hospital for management
till delivery. All children are given the health examinations
in the newborns (<3 days after birth), postnatal period (42
days after birth), infancy (<3 years old), and preschool (3–
7 years old). Tianjin Women and Children’s Health Centre
is the leader of the 3-tier care system and responsible for
organization, coordination, and implementation of women
and child health care, research, and promotion projects.
Health care records for both pregnant women and their
children have been collected and available in electronic
form since 2009 [14]. Pregnant women health records start
within the first 12 weeks of pregnancy and include general
information (age, occupation, education, smoking habits,
etc.), history of diseases, family history of diseases, clinical
measurements (height, weight, blood pressure, gynaecologi-
cal examinations, ultrasonography, GDM screening test, and
other lab tests), complications during pregnancy, pregnancy
outcomes (delivery modes, labor complications, etc.), and
postnatal period examinations (<42 days after delivery, etc.).
Children health records include information from newborns
(date of birth, sex, gestational week of birth, birth weight,
birth length, etc.), postnatal period, and infancy. The infor-
mation of feeding modalities during the first 6 months and
the measurements of recumbent length/height, weight are
collected and available in each health examination. Between
July 2009 and June 2011, 43,854 mother-child pairs’ health
care records were available in central urban districts. The
present study included 27,157 mothers (61.9%) with all infor-
mation, who underwent oral glucose tolerance test (OGTT)
during 26–30 weeks of gestation after excluding 33 mothers
who were diagnosed with diabetes before pregnancy, 3,734
mothersmissing glucose challenge test (GCT), 2,689mothers
missing OGTT, and 10,241 mother-child pairs missing any
variables required for this analysis. Compared with children
excluded in the present study, the children included in the
present analysis had similar age (12.2 versus 12.2 months
old), there were fewer males (51.9% versus 52.8%), and
their mothers were older (28.0 versus 27.0 years old). Of
27,157 mothers, the rates of child health examination at
months 3, 6, 9, and 12 were 88.4%, 90.7%, 94.5%, and 98.3%,
respectively. The study and analysis plan were approved by
Tianjin Women’s and Health’s Health Center Institutional
Review Boards.
2.2. Glucose Testing and GDMDiagnosis. A universal screen-
ing for GDM has become an integral part of the antenatal
care in urban Tianjin [15]. A total of 27,157 pregnant women
at 26–30 gestational weeks underwent OGTT. If pregnant
women had a 1-hour 50 g GCT level ≥7.8mmol/L, they were
asked to undergo a 75 g 2-hour OGTT for GDM diagnosis
test at TianjinWomen’s and Children’s Health Center. OGTT
results were interpreted according to World Health Orga-
nization (WHO) diagnostic criteria [16]. Pregnant mothers
were regrouped into four categories based on the results of
the glycemic screening tests: (1) normal glucose tolerance,
defined as normal results of theGCT (<7.8mmol/L); (2) failed
GCT (≥7.8mmol/L) with normal results on the OGTT, fast-
ing glucose <6.1mmol/L and 2-hour glucose <7.8mmol/L;
(3) impaired glucose tolerance (IGT), defined as failed GCT
and fasting glucose <7.0mmol/L and 2-hour glucose ≥7.8 and
<11.1mmol/L; and (4) newly diagnosed diabetes (new DM),
defined as failed GCT and fasting glucose ≥7.0mmol/L or 2-
hour glucose ≥11.1mmol/L. In the present study, 14 pregnant
mothers were defined as isolated impaired fasting glucose
(IFG), failed GCT and fasting glucose ≥6.1 and <7.0mmol/L
and 2-hour glucose <7.8mmol/L, and these 14 mothers were
included in the IGT group and treated as IGT. GDM was
defined as women with IGT (𝑛 = 1262)/IFG (𝑛 = 14) or new
DM (𝑛 = 144) during 2 h OGTT.
2.3. Measurements. Mothers’ anthropometric data were col-
lected during the pregnancy by obstetricians in the primary
hospitals. Weight and height were measured in light clothing
and no shoes using a beam balance scale (RGZ-120, Jiangsu
SuhongMedical InstrumentsCo., China). Blood pressurewas
measured using a standardizedmercury sphygmomanometer
(XJ11D, Shanghai Medical Instruments Co., China). Chil-
dren’s weight and length were measured at birth, 3 months
(<4 months), 6 months (≥4 and <7 months), 9 months (≥7
and <10 months), and 12 months (≥10 and <13 months).
Weight was measured to the nearest 0.01 kg using a digital
scale (TCS-60, Tianjin Weighing Apparatus Co., China).
Length wasmeasured to the nearest 0.1 cm using a recumbent
length stadiometer (YSC-2, Beijing Guowangxingda, China).
We have done a validity study to compare the electronic
data of measurements of birth weight and hospitals’ mea-
surements of birth weight among 454 children in six major
hospitals. The correlation between two measurements is
0.991. We have also done a validity study to compare the
electronic data of measurements of height and weight with
the same visit’s measurements of height andweight by trained
health workers among 200 pregnant women and 160 children
aged ≤2 years in four different local health centers. The
correlations between electronic data and measurement data
for body weight are 0.998 for pregnant women and 0.999
for children and for height/recumbent length are 0.997 for
pregnant women and 0.999 for children.
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Bodymass index (BMI)was calculated by dividingweight
in kilograms by the square of height in meters. Prepregnancy
BMI was classified as normal weight (BMI < 24 kg/m2), over-
weight (BMI 24–27.9 kg/m2), and obese (BMI ≥ 28 kg/m2)
using the Chinese BMI classification standard [17]. Weight
gain of mothers during pregnancy was calculated as the
difference between prepregnancy and delivery weight. We
categorized women as having gained inadequate, adequate,
or excessive weight according to 2009 American Institute of
Medicine guidelines for weight gain during pregnancy [18].
Z-scores for birth weight-for-gestational age, birth length-
for-gestational age, and birth weight-for-length were calcu-
lated using our own study population mean and standard
deviations. Z-scores for weight-for-age, height-for-age, and
weight-for-length were calculated based on the standards for
the WHO growth reference [19].
2.4. Statistical Analyses. The general characteristics of both
mothers and children according to differentmaternal glucose
concentrations at 26–30 gestational weeks were compared
using General Linear Model and chi-square test. General
Linear Models were used to compare the differences in (1)
Z-scores for birth length and birth weight-for-length; (2) Z-
scores for length-for-age and weight-for-length at months
3, 6, 9, and 12; and (3) changes in Z-scores for length-for-
age and weight-for-length for each three months and from
birth to month 12, according to different maternal glucose
concentrations at 26–30 gestational weeks. We included 3
multivariablemodels in the analyses.Model 1was adjusted for
maternal characters including maternal age, prepregnancy
BMI, weight gain during pregnancy, family history of dia-
betes, education, and family income. To explore the potential
mediating effect, in model 2 we additionally adjusted for
infant feeding status; and in model 3 we additionally adjusted
for birth variables for gestational age Z-score. All statistical
analyses were performed with PASW for Windows, version
20.0 (Statistics 20, SPSS, IBM, USA).
3. Results
The general characteristics of both mothers and children
according to differentmaternal glucose concentrations at 26–
30 gestational weeks are presented in Table 1. Compared with
mothers with normal glucose tolerance, mothers with GDM
were older, had a higher prepregnancy BMI, and had more
inadequate weight gain during pregnancy.
Maternal glucose concentrations at 26–30 gestational
weeks were positively associated with Z-scores for birth
length-for-gestational age and birth weight-for-length
(Table 2). Compared with infants born to mothers with
normal glucose tolerance, infants born to mothers with
GDM had higher mean values of Z-scores for birth length
(new DM 0.23, IGT/IFG 0.07, and normal group −0.08,
𝑃 < 0.001) and birth weight-for-length (new DM 0.57,
IGT/IFG 0.27, normal group −0.001, 𝑃 < 0.001), and lower
mean values of Z-scores for length-for-age at months 3 (new
DM 0.79, IGT/IFG 0.79, normal group 0.87, 𝑃 = 0.007),
6 (new DM 0.82, IGT/IFG 0.89, normal group 0.98,
𝑃 = 0.006), 9 (new DM 0.78, IGT/IFG 0.81, normal group
0.88, 𝑃 = 0.007), and 12 (new DM 0.70, IGT/IFG 0.68,
normal group 0.77, 𝑃 = 0.002) (Table 2), especially among
girls (online Table 1 see Supplementary Materials available
online at: http://dx.doi.org/10.1155/2014/516980). We also
compared mean values of Z-scores for weight-for-age from
birth to months 3, 6, 9, and 12, and the results were similar to
Z-scores for length-for-age and weight-for-length (Figure 1).
Table 3 presents the changes in Z-scores for length-for-
age and weight-for-length for each three months and from
birth to month 12 according to maternal OGTT glucose
concentrations at 26–30 gestational weeks, and these results
analyzed by gender are presented in online Table 2. After
adjustment for maternal age, prepregnancy BMI, weight
gain during pregnancy, family history of diabetes, education,
family income (multivariable model 1), and infant feeding
status (model 2), infants born to mothers with GDM had
smaller changes in mean values of Z-scores for length-for-
age and weight-for length from birth to month 3 and from
birth to month 12 (all 𝑃 < 0.001) compared with those
infants born tomothers with normal glucose tolerance. From
month 9 to 12, changes in mean values of Z-scores for
weight-for-lengthwere bigger among infants born tomothers
with GDM (new DM 0.12, IGT/IFG 0.07) compared with
those infants born to mothers with normal glucose tolerance
(0.02). After additional adjustment for birth variables for
gestational age Z-score (model 3), the smaller changes in
mean values were still significant for length-for-age Z-score
(𝑃 < 0.001) but were not significant for weight-for-length
Z-score (𝑃 = 0.056) from birth to month 12 among infants
born to mothers with new DM compared with those infants
born to mothers with normal glucose tolerance. We did not
find significant differences in changes in Z-scores for body
length andweight-for-length frommonths 3 to 9 according to
maternal OGTT glucose concentrations at 26–30 gestational
weeks. Considering the effect of previous weight or length,
we analyzed percentage change of Z-scores (change in Z-
score between present and previous Z-scores accounting for
previous Z-score) for weight-for-age and length-for-age for
each three months from birth to month 12 according to
maternal OGTT glucose concentrations at 26–30 gestational
weeks (online Figure 1). The percentage change in Z-scores
for weight-for-age from month 3 to 6 and from month 6 to
9 and the percentage change in Z-scores for length-for-age
after month 6 were bigger among infants born to mothers
with new DM compared with those infants born to mothers
with normal glucose tolerance.
4. Discussion
The present study indicated that abnormal maternal glucose
tolerance at 26–30 gestational weeks was associated with
larger birth weight and birth length, less weight and length
gain in the first 3 months of life, and more weight gain in the
months 9–12 of life.
Previous studies have suggested that exposure to the
intrauterine diabetic environment causes larger offspring size
andmore fatness at birth and higher risk of childhood obesity
4 BioMed Research International
Ta
bl
e
1:
Ch
ar
ac
te
ris
tic
so
f2
7,1
57
m
ot
he
r-
in
fa
nt
pa
irs
ac
co
rd
in
g
to
m
at
er
na
lo
ra
lg
lu
co
se
to
le
ra
nc
et
es
t(
O
G
TT
)a
t2
6–
30
ge
st
at
io
na
lw
ee
ks
in
Ti
an
jin
,C
hi
na
.
To
ta
l
M
at
er
na
lO
G
TT
at
26
–3
0
ge
sta
tio
na
lw
ee
ks
𝑃
fo
rd
iff
er
en
ce
s
N
or
m
al
G
CT
+G
CT
an
d
no
rm
al
O
G
TT
IG
T
or
IF
G
N
ew
D
M
N
um
be
ro
fs
ub
je
ct
s
27
15
7
23
50
8
22
29
12
76
14
4
M
at
er
na
lc
ha
ra
ct
er
ist
ic
s
M
at
er
na
la
ge
be
fo
re
pr
eg
na
nc
y,
y
28
.0
(2
.9
)
27
.9
(2
.9
)
28
.2
(3
.0
)
29
.0
(3
.1)
29
.4
(3
.5
)
<
0.
00
1
G
es
ta
tio
na
la
ge
at
de
liv
er
y,
w
k
39
.1
(1
.4
)
39
.1
(1
.4
)
39
.0
(1
.4
)
38
.9
(1
.5
)
38
.3
(1
.7
)
<
0.
00
1
Sy
sto
lic
bl
oo
d
pr
es
su
re
du
rin
g
th
ird
tr
im
es
te
r,
m
m
H
g
10
8
(1
0.
7)
10
8
(1
0.
6)
10
9
(1
0.
9)
110
(1
1.5
)
113
(1
0.
5)
<
0.
00
1
Pr
ep
re
gn
an
cy
BM
I,
kg
/m
2
22
.1
(3
.4
)
22
.0
(3
.3
)
22
.9
(3
.6
)
23
.4
(3
.5
)
26
.0
(4
.0
)
<
0.
00
1
Pr
ep
re
gn
an
cy
BM
Ic
at
eg
or
y,
𝑛
(%
)
<
0.
00
1
U
nd
er
w
ei
gh
t
29
76
(1
1.0
)
27
42
(1
1.7
)
17
1(
7.7
)
62
(4
.9
)
1(
0.
7)
N
or
m
al
w
ei
gh
t
17
51
8
(6
4.
5)
15
43
2
(6
5.
6)
13
22
(5
9.2
)
70
9
(5
5.
5)
55
(3
8.
2)
O
ve
rw
ei
gh
t
50
59
(1
8.
6)
40
96
(1
7.4
)
54
3
(2
4.
4)
37
5
(2
9.4
)
45
(3
1.2
)
O
be
sit
y
16
04
(5
.9
)
12
38
(5
.3
)
19
3
(8
.7
)
13
0
(1
0.
2)
43
(2
9.9
)
G
es
ta
tio
na
lw
ei
gh
tg
ai
n
(I
O
M
ca
te
go
ry
),
𝑛
(%
)
<
0.
00
1
Ex
ce
ss
iv
e
21
46
6
(7
9.0
)
18
68
9
(7
9.5
)
17
39
(7
8.
0)
92
8
(7
2.
7)
11
0
(7
6.
4)
Ad
eq
ua
te
42
87
(1
5.
8)
36
54
(1
5.
5)
36
6
(1
6.
4)
24
7
(19
.4
)
20
(1
3.
9)
In
ad
eq
ua
te
14
04
(5
.2
)
11
65
(5
.0
)
12
4
(5
.6
)
10
1(
7.9
)
14
(9
.7
)
M
ot
he
r’s
ed
uc
at
io
n,
𝑛
(%
)
0.
15
2
U
ni
ve
rs
ity
an
d
ab
ov
e
13
62
4
(5
0.
1)
11
81
1(
50
.2
)
10
87
(4
8.
8)
66
4
(5
2.
1)
62
(4
3.
0)
Ju
ni
or
co
lle
ge
75
96
(2
8.
0)
65
77
(2
8.
0)
62
9
(2
8.
2)
35
0
(2
7.4
)
40
(2
7.8
)
H
ig
h
sc
ho
ol
an
d
un
de
r
59
37
(2
1.9
)
51
20
(2
1.8
)
51
3
(2
3.
0)
26
2
(2
0.
5)
42
(2
9.2
)
Fa
m
ily
in
co
m
e,
yu
an
/m
on
th
∗
,𝑛
(%
)
0.
07
3
≥
30
00
15
87
8
(5
8.
5)
13
73
9
(5
8.
4)
12
82
(5
7.5
)
78
4
(6
1.5
)
73
(5
0.
7)
20
00
–2
99
9
60
87
(2
2.
4)
52
65
(2
2.
4)
50
1(
22
.5
)
28
1(
22
.0
)
40
(2
7.8
)
≤
19
99
51
92
(19
.1)
45
04
(19
.2
)
44
6
(2
0.
0)
21
1(
16
.5
)
31
(2
1.5
)
Ch
ild
ch
ar
ac
te
ris
tic
s
Bo
y,
𝑛
(%
)
14
09
0
(5
1.9
)
12
14
7
(5
1.7
)
117
8
(5
2.
8)
68
4
(5
3.
6)
81
(5
6.
2)
0.
27
6
M
od
eo
fi
nf
an
tf
ee
di
ng
,𝑛
(%
)
0.
04
8
Ex
clu
siv
eb
re
as
tfe
ed
in
g
48
24
(1
7.8
)
42
01
(1
7.9
)
39
7
(1
7.8
)
20
9
(1
6.
4)
17
(1
1.8
)
M
ix
ed
br
ea
st
an
d
fo
rm
ul
a
18
94
0
(6
9.7
)
16
40
0
(6
9.7
)
15
60
(7
0.
0)
88
0
(6
9.0
)
10
0
(6
9.4
)
W
ea
ne
d
fro
m
br
ea
st
fe
ed
in
g
28
87
(1
0.
6)
24
85
(1
0.
6)
22
4
(1
0.
0)
15
5
(1
2.
1)
23
(1
6.
0)
Ex
clu
siv
ef
or
m
ul
af
ee
di
ng
50
6
(1
.9
)
42
2
(1
.8
)
48
(2
.2
)
32
(2
.5
)
4
(2
.8
)
W
ei
gh
t,
kg
Bi
rt
h
3.
39
(0
.4
7)
3.
38
(0
.4
6)
3.
42
(0
.4
8)
3.
45
(0
.5
1)
3.
50
(0
.6
3)
<
0.
00
1
3
m
on
th
s
6.
93
(0
.8
1)
6.
93
(0
.8
1)
6.
95
(0
.8
0)
6.
92
(0
.8
1)
6.
83
(0
.8
0)
0.
34
3
6
m
on
th
s
8.
67
(1
.0
2)
8.
67
(1
.0
2)
8.
68
(1
.0
0)
8.
64
(1
.0
2)
8.
63
(1
.0
4)
0.
71
1
9
m
on
th
s
9.6
9
(1
.11
)
9.6
9
(1
.11
)
9.7
0
(1
.10
)
9.6
6
(1
.11
)
9.7
3
(1
.16
)
0.
71
7
12
m
on
th
s
10
.5
(1
.16
)
10
.5
(1
.16
)
10
.5
(1
.13
)
10
.5
(1
.14
)
10
.5
(1
.32
)
0.
27
2
Le
ng
th
,c
m
Bi
rt
h
50
.1
(1
.6
)
50
.1
(1
.6
)
50
.1
(1
.7
)
50
.2
(1
.6
)
50
.2
(2
.1)
0.
04
6
3
m
on
th
s
62
.9
(2
.3
)
63
.0
(2
.3
)
62
.8
(2
.3
)
62
.8
(2
.3
)
62
.8
(2
.7
)
0.
04
2
6
m
on
th
s
69
.2
(2
.5
)
69
.2
(2
.5
)
69
.1
(2
.4
)
69
.0
(2
.5
)
69
.0
(2
.5
)
0.
07
0
BioMed Research International 5
Ta
bl
e
1:
C
on
tin
ue
d.
To
ta
l
M
at
er
na
lO
G
TT
at
26
–3
0
ge
sta
tio
na
lw
ee
ks
𝑃
fo
rd
iff
er
en
ce
s
N
or
m
al
G
CT
+G
CT
an
d
no
rm
al
O
G
TT
IG
T
or
IF
G
N
ew
D
M
9
m
on
th
s
73
.5
(2
.6
)
73
.5
(2
.6
)
73
.4
(2
.5
)
73
.4
(2
.6
)
73
.3
(2
.5
)
0.
05
8
12
m
on
th
s
77
.1
(2
.7
)
77
.1
(2
.7
)
76
.9
(2
.6
)
76
.9
(2
.6
)
77
.0
(2
.8
)
0.
01
7
D
at
aa
re
m
ea
n
(S
D
)o
rp
er
ce
nt
.
G
CT
:g
lu
co
se
ch
al
le
ng
et
es
t;
IF
G
:i
m
pa
ire
d
fa
sti
ng
gl
uc
os
e;
IG
T:
im
pa
ire
d
gl
uc
os
et
ol
er
an
ce
;N
ew
D
M
:n
ew
ly
di
ag
no
se
d
di
ab
et
es
;B
M
I:
bo
dy
m
as
si
nd
ex
.
N
or
m
al
G
CT
w
as
de
fin
ed
as
a
gl
uc
os
ec
on
ce
nt
ra
tio
n
<
7.8
m
m
ol
/L
aft
er
th
eG
CT
;+
G
CT
an
d
no
rm
al
O
G
TT
w
er
ed
efi
ne
d
as
fa
ile
d
G
CT
(a
gl
uc
os
ec
on
ce
nt
ra
tio
n
≥
7.8
m
m
ol
/L
aft
er
th
eG
CT
)w
ith
no
rm
al
gl
uc
os
e
aft
er
a
75
g
2-
ho
ur
O
G
TT
(fa
sti
ng
gl
uc
os
e
<
6.
1m
m
ol
/L
an
d
2-
ho
ur
gl
uc
os
e
<
7.8
m
m
ol
/L
);
IG
T
w
as
de
fin
ed
as
fa
ile
d
G
CT
an
d
fa
sti
ng
gl
uc
os
e
<
7.0
m
m
ol
/L
an
d
2-
ho
ur
gl
uc
os
e
≥
7.8
an
d
<
11.
1m
m
ol
/L
;I
FG
w
as
de
fin
ed
as
fa
ile
d
G
CT
an
d
fa
sti
ng
gl
uc
os
e≥
6.
1a
nd
<
7.0
m
m
ol
/L
an
d
2-
ho
ur
gl
uc
os
e<
7.8
m
m
ol
/L
;a
nd
ne
w
D
M
w
as
de
fin
ed
as
fa
ile
d
G
CT
an
d
fa
sti
ng
gl
uc
os
e≥
7.0
m
m
ol
/L
or
2-
ho
ur
gl
uc
os
e≥
11.
1m
m
ol
/L
.
6 BioMed Research International
Ta
bl
e
2:
C
om
pa
ris
on
of
Z-
sc
or
es
fo
rb
od
y
le
ng
th
an
d
w
ei
gh
t-f
or
-le
ng
th
fro
m
bi
rt
h
to
m
on
th
s3
,6
,9
,a
nd
12
ac
co
rd
in
g
to
m
at
er
na
lO
G
TT
at
26
–3
0
ge
st
at
io
na
lw
ee
ks
.
To
ta
l
M
at
er
na
lO
G
TT
at
26
–3
0
ge
sta
tio
na
lw
ee
ks
𝑃
fo
rd
iff
er
en
ce
s
N
or
m
al
G
CT
+G
CT
an
d
no
rm
al
O
G
TT
IG
T
or
IF
G
N
ew
D
M
Bi
rt
h
fo
rg
es
ta
tio
na
lw
ee
ks
N
um
be
ro
fs
ub
je
ct
s
27
15
7
23
50
8
22
29
12
76
14
4
Le
ng
th
-fo
r-
ge
st
at
io
na
la
ge
Z-
sc
or
e
−
0.
06
(0
.9
1)
−
0.
08
(0
.9
0)
−
0.
02
(0
.9
1)
0.
07
(0
.9
1)
0.
23
(1
.16
)
<
0.
00
1
W
ei
gh
t-f
or
-le
ng
th
Z-
sc
or
e
0.
03
(1
.0
0)
−
0.
00
1(
0.
98
)
0.
15
(1
.0
1)
0.
27
(1
.0
8)
0.
57
(1
.2
7)
<
0.
00
1
3
m
on
th
s
N
um
be
ro
fs
ub
je
ct
s
24
72
2
21
42
1
20
17
11
54
13
0
Le
ng
th
-fo
r-
ag
eZ
-s
co
re
0.
86
(1
.0
3)
0.
87
(1
.0
3)
0.
81
(1
.0
2)
0.
79
(1
.0
2)
0.
79
(1
.2
0)
0.
00
7
W
ei
gh
t-f
or
-le
ng
th
Z-
sc
or
e
0.
38
(1
.0
4)
0.
37
(1
.0
4)
0.
45
(1
.0
6)
0.
40
(1
.0
6)
0.
30
(1
.0
7)
0.
00
7
6
m
on
th
s
N
um
be
ro
fs
ub
je
ct
s
25
40
0
21
96
0
21
10
119
5
13
5
Le
ng
th
-fo
r-
ag
eZ
-s
co
re
0.
97
(1
.0
6)
0.
98
(1
.0
5)
0.
93
(1
.0
5)
0.
89
(1
.0
5)
0.
82
(1
.0
7)
0.
00
6
W
ei
gh
t-f
or
-le
ng
th
Z-
sc
or
e
0.
70
(1
.0
4)
0.
70
(1
.0
3)
0.
72
(1
.0
8)
0.
70
(1
.0
7)
0.
69
(1
.13
)
0.
70
1
9
m
on
th
s
N
um
be
ro
fs
ub
je
ct
s
22
92
0
19
82
0
18
97
10
89
114
Le
ng
th
-fo
r-
ag
eZ
-s
co
re
0.
87
(1
.0
4)
0.
88
(1
.0
4)
0.
82
(1
.0
3)
0.
81
(1
.0
4)
0.
78
(1
.0
0)
0.
00
7
W
ei
gh
t-f
or
-le
ng
th
Z-
sc
or
e
0.
76
(1
.0
0)
0.
75
(1
.0
0)
0.
79
(1
.0
0)
0.
74
(1
.0
2)
0.
80
(1
.0
5)
0.
42
5
12
m
on
th
s
N
um
be
ro
fs
ub
je
ct
s
23
44
4
20
20
3
19
88
11
30
12
3
Le
ng
th
-fo
r-
ag
eZ
-s
co
re
0.
76
(1
.0
4)
0.
77
(1
.0
4)
0.
71
(1
.0
1)
0.
68
(1
.0
0)
0.
70
(1
.0
8)
0.
00
2
W
ei
gh
t-f
or
-le
ng
th
Z-
sc
or
e
0.
79
(0
.9
8)
0.
78
(0
.9
8)
0.
86
(0
.9
6)
0.
81
(0
.9
8)
0.
84
(1
.0
9)
0.
00
2
D
at
aa
re
m
ea
n
(S
D
).
O
G
TT
:o
ra
lg
lu
co
se
to
le
ra
nc
et
es
t;
IF
G
:i
m
pa
ire
d
fa
sti
ng
gl
uc
os
e;
IG
T:
im
pa
ire
d
gl
uc
os
et
ol
er
an
ce
;N
ew
D
M
:n
ew
ly
di
ag
no
se
d
di
ab
et
es
m
ell
itu
s.
BioMed Research International 7
Ta
bl
e
3:
Ch
an
ge
si
n
Z-
sc
or
es
fo
rb
od
y
le
ng
th
-fo
r-
ag
ea
nd
w
ei
gh
t-f
or
-le
ng
th
fo
re
ac
h
th
re
em
on
th
sa
nd
fro
m
bi
rt
h
to
m
on
th
12
ac
co
rd
in
g
to
m
at
er
na
lO
G
TT
at
26
–3
0
ge
sta
tio
na
lw
ee
ks
.
Ch
an
ge
si
n
Z-
sc
or
es
M
at
er
na
lO
G
TT
at
26
–3
0
ge
sta
tio
na
lw
ee
ks
𝑃
fo
rd
iff
er
en
ce
s
N
or
m
al
G
CT
+G
CT
an
d
no
rm
al
O
G
TT
IG
T
or
IF
G
N
ew
D
M
Fr
om
0
to
3
m
on
th
s
N
o.
of
su
bj
ec
ts
21
41
9
20
17
11
54
13
0
Le
ng
th
-fo
r-
ag
e
M
od
el
1∗
0.
94
(0
.0
1)
0.
86
(0
.0
3)
0.
75
(0
.0
3)
0.
62
(0
.10
)
<
0.
00
1
M
od
el
2†
0.
94
(0
.0
1)
0.
85
(0
.0
3)
0.
76
(0
.0
3)
0.
63
(0
.10
)
<
0.
00
1
M
od
el
3§
0.
94
(0
.0
1)
0.
87
(0
.0
2)
0.
82
(0
.0
3)
0.
76
(0
.0
9)
<
0.
00
1
W
ei
gh
t-f
or
-le
ng
th
M
od
el
1∗
0.
37
(0
.0
1)
0.
32
(0
.0
3)
0.
18
(0
.0
4)
−
0.
17
(0
.11
)
<
0.
00
1
M
od
el
2†
0.
37
(0
.0
1)
0.
32
(0
.0
3)
0.
18
(0
.0
4)
−
0.
16
(0
.11
)
<
0.
00
1
M
od
el
3§
0.
35
(0
.0
1)
0.
39
(0
.0
2)
0.
33
(0
.0
3)
0.
14
(0
.0
9)
0.
02
7
Fr
om
3
to
6
m
on
th
s
N
o.
of
su
bj
ec
ts
20
36
6
19
32
110
2
12
4
Le
ng
th
-fo
r-
ag
e
M
od
el
1∗
0.
11
(0
.0
1)
0.
11
(0
.0
2)
0.
09
(0
.0
3)
0.
02
(0
.0
8)
0.
58
4
M
od
el
2†
0.
11
(0
.0
1)
0.
12
(0
.0
2)
0.
09
(0
.0
3)
0.
02
(0
.0
8)
0.
51
9
M
od
el
3§
0.
11
(0
.0
1)
0.
12
(0
.0
2)
0.
09
(0
.0
3)
0.
02
(0
.0
8)
0.
60
9
W
ei
gh
t-f
or
-le
ng
th
M
od
el
1∗
0.
32
(0
.0
1)
0.
28
(0
.0
2)
0.
29
(0
.0
3)
0.
38
(0
.0
8)
0.
10
7
M
od
el
2†
0.
32
(0
.0
1)
0.
28
(0
.0
2)
0.
29
(0
.0
3)
0.
38
(0
.0
8)
0.
10
8
M
od
el
3§
0.
32
(0
.0
1)
0.
28
(0
.0
2)
0.
28
(0
.0
3)
0.
37
(0
.0
8)
0.
07
5
Fr
om
6
to
9
m
on
th
s
N
o.
of
su
bj
ec
ts
18
99
2
18
27
10
35
110
Le
ng
th
-fo
r-
ag
e
M
od
el
1∗
−
0.
09
(0
.0
1)
−
0.
11
(0
.0
2)
−
0.
09
(0
.0
2)
−
0.
07
(0
.0
7)
0.
83
8
M
od
el
2†
−
0.
09
(0
.0
1)
−
0.
11
(0
.0
2)
−
0.
10
(0
.0
2)
−
0.
07
(0
.0
7)
0.
83
9
M
od
el
3§
−
0.
09
(0
.0
1)
−
0.
10
(0
.0
2)
−
0.
09
(0
.0
2)
−
0.
07
(0
.0
7)
0.
86
0
W
ei
gh
t-f
or
-le
ng
th
M
od
el
1∗
0.
05
(0
.0
1)
0.
06
(0
.0
2)
0.
03
(0
.0
2)
0.
13
(0
.0
7)
0.
57
6
M
od
el
2†
0.
05
(0
.0
1)
0.
06
(0
.0
2)
0.
03
(0
.0
2)
0.
12
(0
.0
7)
0.
58
0
M
od
el
3§
0.
05
(0
.0
1)
0.
06
(0
.0
2)
0.
03
(0
.0
2)
0.
12
(0
.0
7)
0.
56
2
Fr
om
9
to
12
m
on
th
s
N
o.
of
su
bj
ec
ts
17
77
8
17
39
10
13
99
Le
ng
th
-fo
r-
ag
e
M
od
el
1∗
−
0.
12
(0
.0
1)
−
0.
14
(0
.0
2)
−
0.
14
(0
.0
2)
−
0.
10
(0
.0
7)
0.
66
2
M
od
el
2†
−
0.
12
(0
.0
1)
−
0.
14
(0
.0
2)
−
0.
14
(0
.0
2)
−
0.
10
(0
.0
7)
0.
66
3
M
od
el
3§
−
0.
12
(0
.0
1)
−
0.
14
(0
.0
2)
−
0.
14
(0
.0
2)
−
0.
10
(0
.0
7)
0.
68
8
W
ei
gh
t-f
or
-le
ng
th
M
od
el
1∗
0.
02
(0
.0
1)
0.
07
(0
.0
2)
0.
07
(0
.0
2)
0.
12
(0
.0
8)
0.
01
1
M
od
el
2†
0.
02
(0
.0
1)
0.
07
(0
.0
2)
0.
07
(0
.0
2)
0.
12
(0
.0
8)
0.
01
2
M
od
el
3§
0.
02
(0
.0
1)
0.
07
(0
.0
2)
0.
07
(0
.0
2)
0.
12
(0
.0
8)
0.
01
3
8 BioMed Research International
Ta
bl
e
3:
C
on
tin
ue
d.
Ch
an
ge
si
n
Z-
sc
or
es
M
at
er
na
lO
G
TT
at
26
–3
0
ge
sta
tio
na
lw
ee
ks
𝑃
fo
rd
iff
er
en
ce
s
N
or
m
al
G
CT
+G
CT
an
d
no
rm
al
O
G
TT
IG
T
or
IF
G
N
ew
D
M
Fr
om
0
to
12
m
on
th
s
N
o.
of
su
bj
ec
ts
20
20
1
19
88
113
0
12
3
Le
ng
th
-fo
r-
ag
e
M
od
el
1∗
0.
85
(0
.0
1)
0.
73
(0
.0
3)
0.
63
(0
.0
4)
0.
51
(0
.11
)
<
0.
00
1
M
od
el
2†
0.
85
(0
.0
1)
0.
73
(0
.0
3)
0.
63
(0
.0
4)
0.
50
(0
.11
)
<
0.
00
1
M
od
el
3§
0.
84
(0
.0
1)
0.
75
(0
.0
2)
0.
69
(0
.0
3)
0.
62
(0
.0
9)
<
0.
00
1
W
ei
gh
t-f
or
-le
ng
th
M
od
el
1∗
0.
77
(0
.0
1)
0.
71
(0
.0
3)
0.
56
(0
.0
4)
0.
29
(0
.11
)
<
0.
00
1
M
od
el
2†
0.
77
(0
.0
1)
0.
71
(0
.0
3)
0.
56
(0
.0
4)
0.
29
(0
.11
)
<
0.
00
1
M
od
el
3§
0.
76
(0
.0
1)
0.
79
(0
.0
2)
0.
71
(0
.0
3)
0.
61
(0
.0
9)
0.
05
6
D
at
aa
re
m
ea
n
(S
E)
.
IF
G
:i
m
pa
ire
d
fa
sti
ng
gl
uc
os
e;
IG
T:
im
pa
ire
d
gl
uc
os
et
ol
er
an
ce
;N
ew
D
M
:n
ew
ly
di
ag
no
se
d
di
ab
et
es
m
el
lit
us
.
∗
M
od
el
1w
as
ad
ju
ste
d
fo
rm
at
er
na
la
ge
,p
re
pr
eg
na
nc
y
BM
I,
w
ei
gh
tg
ai
n
du
rin
g
pr
eg
na
nc
y,
fa
m
ily
hi
sto
ry
of
di
ab
et
es
,e
du
ca
tio
n
of
m
ot
he
r,
an
d
in
co
m
e.
†
M
od
el
2
w
as
ad
ju
ste
d
fo
ra
bo
ve
va
ria
bl
es
an
d
al
so
m
od
eo
fi
nf
an
tf
ee
di
ng
.
§ M
od
el
3
w
as
ad
ju
ste
d
fo
ra
bo
ve
va
ria
bl
es
an
d
al
so
bi
rt
h
le
ng
th
-fo
r-
ge
st
at
io
na
la
ge
Z-
sc
or
ei
n
ch
an
ge
in
le
ng
th
-fo
r-
ag
eZ
-s
co
re
,b
irt
h
w
ei
gh
t-f
or
-b
irt
h
le
ng
th
Z-
sc
or
ei
n
ch
an
ge
in
w
ei
gh
t-f
or
-le
ng
th
Z-
sc
or
e.
BioMed Research International 9
Birth
−0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Z
-
sc
or
es
 fo
r w
ei
gh
t-f
or
-a
ge
3months 6months 9months 12months
(a)
−0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Z
-
sc
or
es
 fo
r l
en
gt
h-
fo
r-
ag
e
Birth 3months 6months 9months 12months
(b)
Normal GCT
−0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
Z
-
sc
or
es
 fo
r w
ei
gh
t-f
or
-le
ng
th
Birth 3months 6months 9months 12months
+GCT, normal OGTT
IGT or IFG
New DM
(c)
Figure 1: Comparison of Z-scores for bodyweight (a), body length (b), andweight-for-length (c) frombirth tomonths 3, 6, 9, and 12 according
to maternal OGTT at 26–30 gestational weeks.
and young adult IGT and diabetes in the offspring [8, 20].
The offspring of Pima Indian women with preexistent type
2 diabetes and GDM were heavier at birth and had much
higher rates of obesity at age 5–19 than the offspring ofwomen
with prediabetes or without diabetes [21]. However, at what
age this association becomes apparent is unknown because
most of these studies include the GDM’s offspring older than
5 years old [8, 22]. Thus, there is a need to evaluate the
effects of exposure to diabetes in utero on offspring’s health
status among ethnically diverse children with different age
ranges, especially less than 5 years old [8]. The present study
indicated that abnormal maternal glucose tolerance during
pregnancy was associated with larger birth weight and birth
length, lower length-for-age Z-score at months 3, 6, 9, and 12
of age, and more weight gain in the months 9–12 of life.
The present study is, to our knowledge, the first large
prospective study to assess the associations of maternal
glucose tolerance during pregnancy with changes in Z-scores
for length-for-age and weight-for-length each three months
from birth to month 12 in China. We firstly explored the
potential mediating effects of fetal growth on the associa-
tions between maternal OGTT glucose concentrations and
changes in Z-scores from birth to month 3 and found that
abnormal maternal glucose tolerance during pregnancy was
associated with slower weight gain and length gain in the first
3 months of life, which was consistent with earlier findings
from the Project Viva that GDM predicted a slower gain in
weight-for-length Z-scores in the first 6 months of life [12].
The Project Viva also found that higher cord blood leptin
levels were associated with larger size at birth but less weight
gain in the first 6months of life [23]. In addition, we evaluated
the effects of maternal OGTT glucose concentrations on
changes in Z-scores each three months from month 3 to 12,
which could partly decrease the potential mediating effects
of fetal growth on above associations. Although we did not
find any significant differences in weight-for-length Z-scores
from month 3 to 9 among infants born to mothers with
GDM, these infants had more gain in weight-for-length Z-
scores from month 9 to 12 compared with infants born to
mothers with normal glucose tolerance (Table 3). Since our
birth cohort is still ongoing, we can assess the association
of maternal OGTT glucose levels at 26–30 gestational weeks
with offspring growth and development until 7 years old in
the near future. The results of the present study promise to
unravel some knotty questions in the early origins of obesity
and to open up new potential avenues for primordial obesity
prevention.
It is noteworthy that our study found the trend of
rapid gain in weight-for-length Z-scores only among infants
born to mothers with GDM after 9 months of birth. This
10 BioMed Research International
phenomenon may relate with complementary food supple-
ments for infants more than 6–9 months old. In animal
models, maternal hyperglycemia resulted in perinatal hyper-
glycemia and increased hypothalamic insulin levels, followed
by findings of permanent dysplasia of hypothalamic nuclei
regulating food intake and metabolism in the offspring [24].
These alterations may increase food intake, with preference
for fat, and further increase the risk of overweight or obesity
in offspring at adulthood [24, 25]. Thus, early infant diet
on the growth and development of children who may be
programmed for a faster growth trajectorymay be decided by
utero exposure to overnutrition from a diabetic pregnancy.
We found that there was less breastfeeding among infants
born to mothers with GDM than infants born to mothers
with normal glucose during pregnancy, and offspring of
mothers with GDM had more weight gain in the months 9–
12 of life. One study with data from a retrospective cohort
study conducted in Colorado (Exploring Perinatal Outcomes
among Children, EPOCH) reported that the BMI trajectory
was slower among infants in the adequate breastfeeding
category (≥6 breast milk-months) than those infants in the
low breastfeeding category (<6 breast milk-months) between
birth and 9 months of age and between 4 and 6 years of
age, and in both the offspring of diabetic pregnancies and
offspring of nondiabetic pregnancies [26]. Many studies have
shown that formula feeding rather than breastfeeding was
associated with a rapid weight gain in early infancy and a
higher risk of later obesity. The macronutrient compositions
of breast milk (i.e., proteins, fat, and carbohydrate), not
present in formula, may have a protective effect on metabolic
programming and regulation of body fatness and growth
rates [27]. Other studies suggested that breastfeeding might
actually accelerate weight and length gain in the first few
months [28, 29]. In our study, infant feeding status was
considered as a potential medial factor in the association
of maternal OGTT glucose concentrations with children
growth and development in the multivariable analyses but
the association of maternal OGTT glucose with children
growth and development did not significant change after
adjustment for infant feeding status. The present study is an
ongoing project, and long follow-up of our study will assess
association between breastfeeding and long-term effects of
childhood BMI growth that extend beyond infancy into early
and late childhood. Similar to Project Viva, we also found that
the effect estimates for GDM were modestly attenuated after
adjustment for birth variables for gestational age Z-score [12].
However, it is not clear for the effect of birth size on later
growth.
There are several strengths in our study, including the
large sample size of more than 27,000 mother-infant pairs
in which OGTT was performed, repeated direct measures of
maternal weight during pregnancy, repeated direct measures
of the growth and development of infants at birth and each
3 months until 1 year old, and a wide range of potential con-
founders. Our main outcomes included both infant growth
from birth to months 3, 6, 9, and 12 and infant growth each
3 months from month 3 to 12. A limitation of our study
is that we only followed infant growth to 12 months old.
Thus we cannot assess the effect of maternal OGTT glucose
concentrations on offspring’s growth and development after
12 months. However, we will get the children’s later growth
and development information in the near future.
In summary, our study indicated that abnormal maternal
glucose tolerance during pregnancy was associated with
higher birth weight and birth length, less weight gain and
length gain in the first 3 months of life, and more weight
gain in the months 6–12 of life. Intensified intervention of
GDM during pregnancy should be taken to reduce abnormal
glucose metabolism to decrease the risk of infants who are
born to women with GDM becoming overweight or obese in
later life.
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